279 related articles for article (PubMed ID: 31634348)
1. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of Hsh155/SF3b1 interactions with the U2 snRNA/branch site duplex.
Carrocci TJ; Paulson JC; Hoskins AA
RNA; 2018 Aug; 24(8):1028-1040. PubMed ID: 29752352
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
4. Mimicking of splicing-related retinitis pigmentosa mutations in C. elegans allow drug screens and identification of disease modifiers.
Kukhtar D; Rubio-Peña K; Serrat X; Cerón J
Hum Mol Genet; 2020 Mar; 29(5):756-765. PubMed ID: 31919495
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42.
Zhao B; Li Z; Qian R; Liu G; Fan M; Liang Z; Hu X; Wan Y
J Biochem; 2022 Jul; 172(2):117-126. PubMed ID: 35652295
[TBL] [Abstract][Full Text] [Related]
6. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
7. Impact of cancer-associated mutations in Hsh155/SF3b1 HEAT repeats 9-12 on pre-mRNA splicing in Saccharomyces cerevisiae.
Kaur H; Groubert B; Paulson JC; McMillan S; Hoskins AA
PLoS One; 2020; 15(4):e0229315. PubMed ID: 32320410
[TBL] [Abstract][Full Text] [Related]
8. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
9. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
10. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
11. The surveillance of pre-mRNA splicing is an early step in
Newman MA; Ji F; Fischer SEJ; Anselmo A; Sadreyev RI; Ruvkun G
Genes Dev; 2018 May; 32(9-10):670-681. PubMed ID: 29739806
[TBL] [Abstract][Full Text] [Related]
12. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.
Darman RB; Seiler M; Agrawal AA; Lim KH; Peng S; Aird D; Bailey SL; Bhavsar EB; Chan B; Colla S; Corson L; Feala J; Fekkes P; Ichikawa K; Keaney GF; Lee L; Kumar P; Kunii K; MacKenzie C; Matijevic M; Mizui Y; Myint K; Park ES; Puyang X; Selvaraj A; Thomas MP; Tsai J; Wang JY; Warmuth M; Yang H; Zhu P; Garcia-Manero G; Furman RR; Yu L; Smith PG; Buonamici S
Cell Rep; 2015 Nov; 13(5):1033-45. PubMed ID: 26565915
[TBL] [Abstract][Full Text] [Related]
14. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the aberrant splicing of DVL2 induced by cancer-associated SF3B1 mutation.
Zhao B; Hu X; Zhou Y; Shi Y; Qian R; Wan Y
Biochem Biophys Res Commun; 2021 Mar; 546():21-28. PubMed ID: 33561744
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
17. The Caenorhabditis elegans gene mfap-1 encodes a nuclear protein that affects alternative splicing.
Ma L; Gao X; Luo J; Huang L; Teng Y; Horvitz HR
PLoS Genet; 2012; 8(7):e1002827. PubMed ID: 22829783
[TBL] [Abstract][Full Text] [Related]
18. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
19. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.
Lee SC; North K; Kim E; Jang E; Obeng E; Lu SX; Liu B; Inoue D; Yoshimi A; Ki M; Yeo M; Zhang XJ; Kim MK; Cho H; Chung YR; Taylor J; Durham BH; Kim YJ; Pastore A; Monette S; Palacino J; Seiler M; Buonamici S; Smith PG; Ebert BL; Bradley RK; Abdel-Wahab O
Cancer Cell; 2018 Aug; 34(2):225-241.e8. PubMed ID: 30107174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
